William J. Stromberg
William J. Stromberg's purchase track record
William J. Stromberg has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/6/2026 | GEHC | $62K | +13.8% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
T. Rowe Price Faces Advisor Hiring Push and Dividend Debate. T. Rowe Price is testing its growth strategy with a new advisor hiring push, while analysts note a modest fair‑value cut amid mixed views. The firm’s dividend yield of 4.97% keeps it in the conversation with other dividend leaders, and a recent 38% share drop has led some to label it undervalued. Earnings expectations are being watched closely as the company prepares its next quarterly report.
Transaction History
| GEHC | ▲ Buy | Grant | 3,586 | $0 | 5/7/2026 | View on chart |
| GEHC | ▲ Buy | Open Market | 1,000 | $62K | 5/6/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 3,092 | $0 | 5/28/2025 | View on chart |
| GEHC | ▲ Buy | Grant | 2,037 | $0 | 5/28/2025 | View on chart |
| GEHC | ▲ Buy | Grant | 2,440 | $0 | 5/21/2024 | View on chart |
| GEHC | ▲ Buy | Grant | 1,769 | $0 | 5/21/2024 | View on chart |
| TROW | ▼ Sell | Gift | 49,900 | $0 | 2/29/2024 | View on chart |
| TROW | ▼ Sell | Gift | 49,900 | $0 | 2/29/2024 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 3,558 | $394K | 2/28/2024 | View on chart |
| TROW | ▲ Buy | Grant | 19,260 | $0 | 2/16/2024 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 10,799 | $1.1M | 12/8/2023 | View on chart |
| TROW | ▼ Sell | Gift | 5,000 | $0 | 11/16/2023 | View on chart |
| TROW | ▼ Sell | Gift | 5,000 | $0 | 11/16/2023 | View on chart |
| TROW | ▼ Sell | Open Market | 5,000 | $492K | 11/15/2023 | View on chart |
| TROW | ▼ Sell | Open Market | 5,000 | $492K | 11/15/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 3,584 | $0 | 5/23/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 1,408 | $0 | 5/23/2023 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 3,206 | $358K | 2/28/2023 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 3,618 | $404K | 2/28/2023 | View on chart |
| TROW | ▲ Buy | Grant | 23,388 | $0 | 2/14/2023 | View on chart |
| TROW | ▼ Sell | Gift | 54,000 | $0 | 12/23/2022 | View on chart |
| TROW | ▼ Sell | Gift | 54,000 | $0 | 12/23/2022 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 9,009 | $1.1M | 12/9/2022 | View on chart |
| TROW | ▼ Sell | Gift | 16,000 | $0 | 11/14/2022 | View on chart |
| TROW | ▼ Sell | Gift | 16,000 | $0 | 11/14/2022 | View on chart |
| TROW | ▼ Sell | Open Market | 10,000 | $1.2M | 11/11/2022 | View on chart |
| TROW | ▼ Sell | Gift | 36,000 | $0 | 5/13/2022 | View on chart |
| TROW | ▼ Sell | Gift | 36,000 | $0 | 5/13/2022 | View on chart |
| TROW | ▲ Buy | Option Exercise | 1,254 | $100K | 3/7/2022 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 4,444 | $646K | 2/28/2022 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 3,206 | $466K | 2/28/2022 | View on chart |
| TROW | ▼ Sell | Open Market | 2,797 | $561K | 12/28/2021 | View on chart |
| TROW | ▼ Sell | Open Market | 7,647 | $1.5M | 12/28/2021 | View on chart |
| TROW | ▼ Sell | Open Market | 4,556 | $906K | 12/28/2021 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 8,913 | $1.8M | 12/10/2021 | View on chart |
| TROW | ▲ Buy | Grant | 16,160 | $0 | 12/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
GEHC Secures CE Mark for MINItrace Magni Cyclotron
GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.
GEHC Secures CE Mark for MINItrace Magni Cyclotron. GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.